National Vision (EYE) Competitors

$17.70
+0.28 (+1.61%)
(As of 05/1/2024 ET)

EYE vs. WRBY, RXST, STAA, BLCO, MORF, ESTA, AKRO, AGTI, RCUS, and ANIP

Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include Warby Parker (WRBY), RxSight (RXST), STAAR Surgical (STAA), Bausch + Lomb (BLCO), Morphic (MORF), Establishment Labs (ESTA), Akero Therapeutics (AKRO), Agiliti (AGTI), Arcus Biosciences (RCUS), and ANI Pharmaceuticals (ANIP).

National Vision vs.

Warby Parker (NYSE:WRBY) and National Vision (NASDAQ:EYE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.

93.2% of Warby Parker shares are held by institutional investors. 26.9% of Warby Parker shares are held by insiders. Comparatively, 2.1% of National Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Warby Parker currently has a consensus price target of $16.29, suggesting a potential upside of 35.94%. National Vision has a consensus price target of $23.86, suggesting a potential upside of 34.79%. Given National Vision's stronger consensus rating and higher probable upside, equities research analysts plainly believe Warby Parker is more favorable than National Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38
National Vision
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

National Vision received 230 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 66.06% of users gave National Vision an outperform vote while only 32.86% of users gave Warby Parker an outperform vote.

CompanyUnderperformOutperform
Warby ParkerOutperform Votes
23
32.86%
Underperform Votes
47
67.14%
National VisionOutperform Votes
253
66.06%
Underperform Votes
130
33.94%

Warby Parker has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

National Vision has a net margin of -3.10% compared to National Vision's net margin of -9.44%. Warby Parker's return on equity of 3.69% beat National Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker-9.44% -16.36% -8.66%
National Vision -3.10%3.69%1.41%

In the previous week, National Vision had 7 more articles in the media than Warby Parker. MarketBeat recorded 12 mentions for National Vision and 5 mentions for Warby Parker. National Vision's average media sentiment score of 0.95 beat Warby Parker's score of 0.29 indicating that Warby Parker is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
National Vision
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Warby Parker has higher earnings, but lower revenue than National Vision. Warby Parker is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$669.77M1.77-$63.20M-$0.54-22.19
National Vision$2.13B0.65-$65.90M-$0.85-20.82

Summary

Warby Parker beats National Vision on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYE vs. The Competition

MetricNational VisionSpecialty Retail IndustryCyclical SectorNASDAQ Exchange
Market Cap$1.39B$3.92B$2.54B$7.42B
Dividend YieldN/A5.03%4.41%3.96%
P/E Ratio-20.82326.33339.9219.13
Price / Sales0.6530.22248.0789.78
Price / Cash10.0212.2223.8035.54
Price / Book1.672.642.364.27
Net Income-$65.90M$269.82M$173.97M$214.24M
7 Day Performance-0.95%-0.38%0.09%1.20%
1 Month Performance-15.43%-0.21%-1.40%-3.86%
1 Year Performance-17.94%-4.55%7.43%8.19%

National Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WRBY
Warby Parker
2.5514 of 5 stars
$11.74
-5.9%
$16.29
+38.8%
+7.6%$1.16B$669.77M-21.733,491Upcoming Earnings
RXST
RxSight
1.5704 of 5 stars
$52.13
-2.1%
$49.63
-4.8%
+201.6%$1.94B$89.08M-36.45374Upcoming Earnings
STAA
STAAR Surgical
4.6559 of 5 stars
$45.96
-3.1%
$46.38
+0.9%
-38.6%$2.26B$322.42M106.881,115Upcoming Earnings
BLCO
Bausch + Lomb
3.4256 of 5 stars
$14.54
-3.8%
$19.50
+34.1%
-21.6%$5.11B$4.15B-19.6513,300Analyst Report
Short Interest ↑
News Coverage
MORF
Morphic
3.7255 of 5 stars
$27.27
-2.5%
$51.50
+88.9%
-43.4%$1.37B$520,000.00-7.79121Positive News
ESTA
Establishment Labs
0.3644 of 5 stars
$50.01
+2.1%
$55.00
+10.0%
-29.0%$1.37B$165.15M-16.45908Upcoming Earnings
News Coverage
AKRO
Akero Therapeutics
3.1883 of 5 stars
$19.89
+1.4%
$37.71
+89.6%
-55.3%$1.38BN/A-6.9855News Coverage
AGTI
Agiliti
1.7731 of 5 stars
$10.15
+0.3%
$14.17
+39.6%
+392.7%$1.38B$1.17B-72.495,800
RCUS
Arcus Biosciences
2.411 of 5 stars
$15.24
-2.5%
$41.25
+170.7%
-15.9%$1.39B$117M-3.67577Upcoming Earnings
News Coverage
ANIP
ANI Pharmaceuticals
4.4253 of 5 stars
$66.00
+0.8%
$80.00
+21.2%
+74.5%$1.39B$486.82M78.57642Short Interest ↑

Related Companies and Tools

This page (NASDAQ:EYE) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners